Daily Stock Opinions and Ratings

Opinions

David BaskinNovelionNVLN.TODON'T BUYJul 07, 2004

Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this.

David Baskin

Unlock Rating

$25.09

Stock price when the opinion was issued

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY ON WEAKNESS

(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.

SELL

The future isn't bright. Losing market share with their main product. Suggests tax loss selling.

DON'T BUY

Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.

SELL

The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.

DON'T BUY

The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.

DON'T BUY

Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.

WAIT

Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.

DON'T BUY

A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.

SELL

Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.

DON'T BUY

This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.

DON'T BUY

Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.

WEAK BUY

Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.

DON'T BUY

You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.

DON'T BUY

Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.

WAIT

Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

David BaskinNovelionNVLN.TODON'T BUYJul 07, 2004

You might be interested:

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Novelion(NVLN.TO)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Jim Cramer - Mad Money

Richard Orrell

Stockchase Insights

The Panic-Proof Portfolio (Stockchase Research)

Stan Wong